GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » G.Barekat Pharm (XTEH:BRKT1) » Definitions » Additional Paid-In Capital

G.Barekat Pharm (XTEH:BRKT1) Additional Paid-In Capital : IRR0 Mil(As of Mar. 2017)


View and export this data going back to 2017. Start your Free Trial

What is G.Barekat Pharm Additional Paid-In Capital?



G.Barekat Pharm Additional Paid-In Capital Historical Data

The historical data trend for G.Barekat Pharm's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

G.Barekat Pharm Additional Paid-In Capital Chart

G.Barekat Pharm Annual Data
Trend Mar16 Mar17
Additional Paid-In Capital
- -

G.Barekat Pharm Semi-Annual Data
Mar16 Mar17
Additional Paid-In Capital - -

G.Barekat Pharm Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

G.Barekat Pharm Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of G.Barekat Pharm's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


G.Barekat Pharm (XTEH:BRKT1) Business Description

Traded in Other Exchanges
N/A
Address
No. 11, 5th Alley, Bucharest Avenue, Argentina Square, Tehran, IRN
G.Barekat Pharm focuses on the introduction of new pharmaceutical fields such as biotechnology, drug delivery which includes nanotechnology, slow release drugs, and new technologies for health, development of cellular molecular industries like tuberculosis, gene therapy, immunotherapy, and tissue technology.

G.Barekat Pharm (XTEH:BRKT1) Headlines

No Headlines